Combination of the SGLT2i Dapagliflozin and carbohydrate restriction in patients with T2D and obesity resulted in a significant reduction of weight, fat mass and serum leptin, with no discernible change in energy expenditure or appetite at 12 months. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.